Glutamine metabolic reprogramming in acute and chronic kidney diseases: mechanistic insights and therapeutic implications
4 affiliations
- 1Department of Nephrology, Xijing Hospital, Fourth Military Medical University
- 2Shaanxi Provincial Clinical Research Center for Kidney Diseases
- 3Fundamental Medical Science Research Laboratories, the 940th Hospital Joint Logistics Support Forces of the People’s Liberation Army
- 4Department of Geriatric, Xijing Hospital, Fourth Military Medical University
Abstract
Acute kidney injury (AKI) and chronic kidney disease (CKD) are common clinical disorders that have high incidence and mortality. Their pathogenesis and the mechanisms underlying AKI-to-CKD progression remain unclear. Metabolic reprogramming has emerged as a core mechanism driving the onset and progression of kidney diseases. Glutamine (Gln) metabolism, a central component of renal energy metabolism, not only maintains acid-base balance and cellular homeostasis but also actively participates in pathophysiological processes including ischemic injury, oxidative stress, inflammatory regulation and fibrosis. Multi-omics studies have revealed stage-specific alterations in Gln metabolism-associated signatures during kidney injury. In AKI, altered Gln levels and redox-related metabolites may suggest disturbances in metabolic pathways, whereas in CKD, elevated glutaminase 1 (GLS1) expression and glutaminolysis-associated metabolic reprogramming are associated with fibrosis. Gln, as an immunonutrient, also serves as a critical energy substrate to sustain the proliferation, activation, and effector functions of immune cells. Gln metabolism may reshape the immune microenvironment within the injured kidney, thereby modulating disease progression. Targeting the Gln metabolic axis may offer new therapeutic insights for AKI and CKD. However, the changes in Gln metabolism and its consequent immunometabolic effects during the AKI-to-CKD transition remain poorly understood. This narrative review aims to provide a comprehensive overview of the dynamic changes in Gln metabolism during acute and chronic kidney diseases, its stage-specific mechanisms, and its potential as a therapeutic target. We also seek to provide a theoretical basis for developing novel biomarkers and targeted therapies based on Gln metabolic reprogramming.
Related
- RNA-binding proteins in tumor lipid metabolic reprogramming: from mechanistic understanding to targeted therapy
- BORIS in Hormone-Driven Cancers: Epigenetic Reprogramming, Transcriptional Plasticity, and Therapeutic Implications
- Immune cell metabolic reprogramming in pancreatic cancer: roles in tumor progression and therapeutic strategies
- Orexin deficiency and cardiometabolic risk in narcolepsy: mechanistic pathways and therapeutic implications
- Metabolic reprogramming in the immune microenvironment of Ewing sarcoma: from mechanisms to therapeutic strategies
BibTeX
@article{xu2026glutamine,
title = {{Glutamine metabolic reprogramming in acute and chronic kidney diseases: mechanistic insights and therapeutic implications}},
author = {Ruotong Xu and Jin Zhao and Minna Liu and Yifan Qiao and Xiaoxuan Ning and Shiren Sun},
journal = {Frontiers in Immunology},
year = {2026},
month = oct,
doi = {10.3389/fimmu.2026.1939528},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1939528/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Glutamine metabolic reprogramming in acute and chronic kidney diseases: mechanistic insights and therapeutic implications
AU - Ruotong Xu
AU - Jin Zhao
AU - Minna Liu
AU - Yifan Qiao
AU - Xiaoxuan Ning
AU - Shiren Sun
PY - 2026
DA - 2026/10/12
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1939528
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1939528/full
AB - Acute kidney injury (AKI) and chronic kidney disease (CKD) are common clinical disorders that have high incidence and mortality. Their pathogenesis and the mechanisms underlying AKI-to-CKD progression remain unclear. Metabolic reprogramming has emerged as a core mechanism driving the onset and progression of kidney diseases. Glutamine (Gln) metabolism, a central component of renal energy metabolism, not only maintains acid-base balance and cellular homeostasis but also actively participates in pathophysiological processes including ischemic injury, oxidative stress, inflammatory regulation and fibrosis. Multi-omics studies have revealed stage-specific alterations in Gln metabolism-associated signatures during kidney injury. In AKI, altered Gln levels and redox-related metabolites may suggest disturbances in metabolic pathways, whereas in CKD, elevated glutaminase 1 (GLS1) expression and glutaminolysis-associated metabolic reprogramming are associated with fibrosis. Gln, as an immunonutrient, also serves as a critical energy substrate to sustain the proliferation, activation, and effector functions of immune cells. Gln metabolism may reshape the immune microenvironment within the injured kidney, thereby modulating disease progression. Targeting the Gln metabolic axis may offer new therapeutic insights for AKI and CKD. However, the changes in Gln metabolism and its consequent immunometabolic effects during the AKI-to-CKD transition remain poorly understood. This narrative review aims to provide a comprehensive overview of the dynamic changes in Gln metabolism during acute and chronic kidney diseases, its stage-specific mechanisms, and its potential as a therapeutic target. We also seek to provide a theoretical basis for developing novel biomarkers and targeted therapies based on Gln metabolic reprogramming.
SN - 1664-3224
ER -